Cogent Biosciences (COGT) Operating Margin (2017 - 2020)
Cogent Biosciences (COGT) posted quarterly Operating Margin of 18333.01% for Q3 2020, down 1715301.0% year-over-year from N/an in Q4 2019, and down 1207.56% quarter-over-quarter from 1402.08% in Q2 2020.
Cogent Biosciences (COGT) Operating Margin (2017 - 2020) Analysis & Trends
Cogent Biosciences (COGT) has reported Operating Margin for 4 consecutive years, with 18333.01% the latest figure, recorded in Q3 2020.
- In Q3 2020, Operating Margin fell 1715301.0% year-over-year to 18333.01%; the TTM figure through Dec 2020 stood at 1044.33% (down 90131.0% YoY), while the FY2020 annual figure was 1044.33%, down 90131.0% from the prior year.
- Operating Margin retreated to 18333.01% in Q3 2020 per COGT's latest filing, from 1402.08% in the prior quarter.
- Across five years, Operating Margin topped out at 14.65% in Q4 2019 and bottomed at 18333.01% in Q3 2020.
- Historically, Operating Margin has averaged 1640.08% across 4 years, with a median of 332.18% in 2017.
- On a YoY basis, Operating Margin climbed as much as 30051 bps in 2020 and fell as far as 1715301 bps in 2020.
- Cogent Biosciences' Operating Margin stood at 324.07% in 2017, then rose by 27 bps to 236.64% in 2018, then soared by 106 bps to 14.65% in 2019, then plunged by 125223 bps to 18333.01% in 2020.
- Business Quant data shows COGT's Operating Margin at 18333.01% in Q3 2020, 1402.08% in Q2 2020, and 87.34% in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -18,333.01% |
| Jun 30, 2020 | -1,402.08% |
| Mar 31, 2020 | -87.34% |
| Dec 31, 2019 | 14.65% |
| Sep 30, 2019 | -1,180.00% |
| Jun 30, 2019 | -335.91% |
| Mar 31, 2019 | -387.85% |
| Dec 31, 2018 | -236.64% |
| Sep 30, 2018 | -517.67% |
| Jun 30, 2018 | -566.57% |
| Mar 31, 2018 | -314.68% |
| Dec 31, 2017 | -324.07% |
| Sep 30, 2017 | -307.59% |
| Jun 30, 2017 | -290.19% |
| Mar 31, 2017 | -332.18% |